(+/-)3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl) ethoxy]phenyl]-2-ethoxypropanoic acid dicyclohexylamine salt | 446291-57-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: (+/-)3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl) ethoxy]phenyl]-2-ethoxypropanoic acid dicyclohexylamine salt
• 英文别名: N-cyclohexylcyclohexanamine;2-ethoxy-3-[4-[2-(2-ethyl-4-oxoquinazolin-3-yl)ethoxy]phenyl]propanoic acid
• CAS: 446291-57-2
• 化学式: C₁₂H₂₃N*C₂₃H₂₆N₂O₅
• 分子量: 591.791
• InChiKey: IPIQBVLYAZBZSC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.31
• 重原子数：
  43
• 可旋转键数：
  12
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Pharmaceutically acceptable salts of heterocyclic compounds
  申请人：DR. REDDY'S LABORATORIES LTD.

  公开号：US20020169175A1

  公开（公告）日：2002-11-14

  The present invention relates to pharmaceutically acceptable salts of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. 1

  本发明涉及通式（I）的药用可接受盐，它们的衍生物、类似物、互变异构体、立体异构体、多型体、药用可接受溶剂合物以及含有它们的药用可接受组合物。
• SALTS OF PYRIMIDINE DERIVATIVES FOR USE AGAINST CORONARY HEART DISEASE AND ATHEROSCLEROSE
  申请人：Dr. Reddy's Laboratories Ltd.

  公开号：EP1363913A2

  公开（公告）日：2003-11-26
• [EN] PHARMACEUTICALLY ACCEPTABLE SALTS OF HETEROCYCLIC COMPOUNDS<br/>[FR] SELS DE COMPOSES HETEROCYCLIQUES PHARMACEUTIQUEMENT ACCEPTABLES
  申请人：REDDY RESEARCH FOUNDATION

  公开号：WO2002062798A2

  公开（公告）日：2002-08-15

  The present invention relates to pharmaceutically acceptable salts of compound of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. The present invention relates to pharmaceutically acceptable salts of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs and pharmaceutically acceptable compositions containing them.